Affiliation:
1. Department of Neurosurgery, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
Abstract
Glioblastoma (GBM) is a highly aggressive primary brain tumor that is largely refractory to treatment and, therefore, invariably relapses. GBM patients have a median overall survival of 15 months and, given this devastating prognosis, there is a high need for therapy improvement. One of the therapeutic approaches currently tested in GBM is chimeric antigen receptor (CAR)-T cell therapy. CAR-T cells are genetically altered T cells that are redirected to eliminate tumor cells in a highly specific manner. There are several challenges to CAR-T cell therapy in solid tumors such as GBM, including restricted trafficking and penetration of tumor tissue, a highly immunosuppressive tumor microenvironment (TME), as well as heterogeneous antigen expression and antigen loss. In addition, CAR-T cells have limitations concerning safety, toxicity, and the manufacturing process. To date, CAR-T cells directed against several target antigens in GBM including interleukin-13 receptor alpha 2 (IL-13Rα2), epidermal growth factor receptor variant III (EGFRvIII), human epidermal growth factor receptor 2 (HER2), and ephrin type-A receptor 2 (EphA2) have been tested in preclinical and clinical studies. These studies demonstrated that CAR-T cell therapy is a feasible option in GBM with at least transient responses and acceptable adverse effects. Further improvements in CAR-T cells regarding their efficacy, flexibility, and safety could render them a promising therapy option in GBM.
Reference125 articles.
1. Ou, A., Alfred Yung, W.K., and Majd, N. (2021). Molecular Mechanisms of Treatment Resistance in Glioblastoma. Int. J. Mol. Sci., 22.
2. Immunotherapy for Glioblastoma: Adoptive T-Cell Strategies;Choi;Clin. Cancer Res.,2019
3. Berger, M.S., and Weller, E.S. (2016). Handbook of Clinical Neurology, Elsevier.
4. Adult glioblastoma;Alexander;J. Clin. Oncol.,2017
5. Dymova, M.A., Kuligina, E.V., and Richter, V.A. (2021). Molecular Mechanisms of Drug Resistance in Glioblastoma. Int. J. Mol. Sci., 22.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献